Prostate cancer drug combo gets a formulation check

NCT ID NCT04577833

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study looks at how the body absorbs different versions of two prostate cancer drugs, niraparib and abiraterone acetate, taken together with prednisone. It involves 136 men with metastatic castration-resistant prostate cancer. The goal is to compare the absorption of various tablet strengths and forms, not to test if the drugs work against the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: niraparib and abiraterone acetate (with prednisone)
What this could lead to: If successful, this study could help identify the best formulation of these drugs for future use, potentially improving treatment convenience or effectiveness for men with prostate cancer.
What could go wrong: This is an early Phase 1 trial focused on drug absorption, not on curing or controlling the cancer itself. The results may not lead to any direct benefit for participants or change current treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

Contacts and locations

Locations

ARENSIA Exploratory Medicine Unit

Kyiv, 01135, Ukraine
Arensia Exploratory Medicine

Chisinau, Md2025, Moldova
Arensia Exploratory Medicine 1

Tbilisi, 0112, Georgia
Erasmus MC

Rotterdam, 3015 GD, Netherlands
GZA Ziekenhuizen- Campus St Augustinus

Wilrijk, 2610, Belgium
HIA Begin

Saint-Mandé, 94163, France
Hosp Univ Fund Jimenez Diaz

Madrid, 28040, Spain
Hosp Univ Hm Sanchinarro

Madrid, 28050, Spain
Hosp Virgen de La Victoria

Málaga, 29010, Spain
Institut Bergonié, Centre de Lutte Contre le Cancer

Bordeaux, 33000, France
Karolinska Universitetssjukhuset Solna

Stockholm, 171 76, Sweden
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy

Warsaw, 02-781, Poland
START Mountain Region

West Valley City, Utah, 84119, United States
Sir Bobby Robson Unit, Northern Centre for Cancer Care

Newcastle upon Tyne, NE7 7DN, United Kingdom
Universitair Ziekenhuis Gent

Ghent, 9000, Belgium
Uniwersyteckie Centrum Kliniczne

Gdansk, 80 214, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.